News

The group medical director of neuroscience at Genentech spoke to the findings recently presented at the 6th Annual Meeting of the European Academy of Neurology.

Carrie Hersh, DO, MSc, assistant professor of neurology at the Cleveland Clinic Lerner College of Medicine, discusses recent data on natalizumab as well as what sets it apart from other multiple sclerosis treatments.

After respective approvals in December 2019 and March 2020, lemborexant (Dayvigo; Eisai) and ozanimod (Zeposia; Bristol Myers Squibb) have become available for patients with insomnia and multiple sclerosis.

The AHS fellow, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital spoke to what to expect from this year’s annual scientific meeting.

Coutinho et al. noted that future studies that feature a larger population will help to better determine recovery rates after endovascular treatment.

Approximately one-fourth of the excess cases of maternal stroke associated with migraine were attributable to hypertensive disorders.

The founding executive director and chief science officer of the Alzheimer’s Drug Discovery Foundation discussed the recent approval of the imaging agent flortaucipir F18.

The clinical healthy psychology fellow at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the reasoning behind his study evaluating conformity of masculine norms in patients with multiple sclerosis.

The first study to attempt to directly compare 3 debated treatment strategies to treat medication overuse headache showed the most significant change in monthly headache days by using withdrawal plus preventive treatment.

Head of Global Clinical Development in Neurology at EMD Serono discussed the findings of a phase 2 assessment of the company’s investigational BTK inhibitor evobrutinib in multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 5, 2020.

The Adamas Pharmaceuticals agent has a PDUFA action date of February 1, 2021, as a treatment for off episodes in patients with Parkinson disease who are receiving levodopa-based therapy.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Shadi Yaghi, MD.

The Nippon Shinkyaku therapy also showed no treatment-emergent adverse events that required reduction, interruption, or discontinuation of the treatment.

The GERA-US study assessed societal costs associated with MCI and mild dementia, and caring for someone with Alzheimer disease, and was the first such study to show how the early stages of cognitive decline economically impact both patients and their caregivers.

Post-hoc data presented at the EAN Congress suggest patients with dyskinesia prior to starting treatment on the Kyowa Kirin agent were more likely to experience dyskinesia as an adverse event during treatment.

The assistant professor and director of Clinical Vascular Neurology Research at NYU Langone shares his reaction to data that has been published and what needs to be researched going forward.

Non-work-related activity impairment was statistically significantly reduced in the galcanezumab group compared to placebo.

The chief of pediatric neurology at the University of Tennessee Health Science Center, and director of the Comprehensive Epilepsy Program at Le Bonheur Children's Hospital spoke to the difficulty in connecting with colleagues with virtual meetings.

Incident impulse control disorder behaviors through the 5-year follow-up period were correlated with dopamine agonist use and depression, but not with age.

Raising glucose levels may prove to be a simple and novel technique for the prevention and treatment of post-dural puncture headache.

The anti-CD20 monoclonal antibody had an original PDUFA date of June 2020.

The professor and head of the department of neurology at the University of Minnesota spoke to the recent findings of a study of Boston Scientific's multiple independent contact current-controlled device for deep brain stimulation.

Cenobamate may offer a potential treatment option for patients who continue to have seizures despite the use of available treatments.

The study authors noted that the findings suggest that integrating a cost-effective and safe intervention such as yoga into the management of migraine would be beneficial.

The chief of pediatric neurology at the University of Tennessee Health Science Center, and director of the Comprehensive Epilepsy Program at Le Bonheur Children's Hospital discussed the current state of research in epilepsy care.

Topline results from the phase 3 trial of arimoclomol are expected to be announced in the first half of 2021.

The professor and head of the department of neurology at the University of Minnesota discussed what multiple independent contact current-controlled devices offer physicians conducting deep brain stimulation.